Understanding solid-phase HLA antibody assays and the value of MFI
10.1016/j.humimm.2017.05.007 · 2017
Is there a role for desensitization in intestinal transplantation?
10.1177/1526924819855088 · 2019
Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin
10.1097/01.tp.0000226078.94635.76 · 2006
The impact of antibodies and virtual crossmatching on intestinal transplant outcomes
10.1097/mot.0000000000000393 · 2017
Donor-specific antibody and sensitized patients in intestinal transplantation
10.1097/mot.0000000000000853 · 2021
Immunology of the small intestine
10.1016/s0041-1345(98)00725-8 · 1998
Antagonistic effect of toll-like receptor signaling and bacterial infections on transplantation tolerance
10.1097/tp.0b013e3181a2b90f · 2009
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance
10.1002/hep.1840170629 · 1993
Replacement of donor lymphoid tissue in small-bowel transplants
10.1016/0140-6736(91)92517-6 · 1991
Immunologic challenges in small bowel transplantation
10.1111/j.1600-6143.2012.04332.x · 2012
Summary of FDA antibody-mediated rejection workshop
10.1111/j.1600-6143.2011.03525.x · 2011
Application, technical issues, and interpretation of C1q for graft outcome
10.1097/mot.0000000000000454 · 2017
C1Q assay results in complement-dependent cytotoxicity crossmatch negative renal transplant candidates with donor-specific antibodies: high specificity but low sensitivity when predicting flow crossmatch
2016
Complement-binding anti-HLA antibodies and kidney-allograft survival
10.1056/nejmoa1302506 · 2013
Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation
10.1111/tri.12873 · 2017
C1q test for identification of sensitized liver recipients at risk of early acute antibody-mediated rejection
10.12659/aot.904867 · 2017
313.7: Impact of C1q-fixing donor-specific antibodies on pancreas transplant outcomes
10.1097/01.tp.0000994344.87865.0a · 2023
Donor-specific human leukocyte antigen antibodies in intestinal transplantation
10.1097/mot.0000000000000078 · 2014
Emerging new approaches in desensitization: targeted therapies for HLA sensitization
10.3389/fimmu.2021.694763 · 2021
Current approaches to desensitization in solid organ transplantation
10.3389/fimmu.2021.686271 · 2021
Update on desensitization strategies and drugs on hyperimmune patients for kidney transplantation
2023
Bortezomib: a new player in pre- and post-transplant desensitization?
10.1093/ndt/gfq502 · 2010
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients
10.1111/j.1600-6143.2011.03757.x · 2011
Potential roles for C1 inhibitor in transplantation
10.1097/tp.0000000000000995 · 2016
Successful living donor intestinal transplantation in cross-match positive recipients: initial experience
10.4240/wjgs.v8.i1.101 · 2016
Impact of positive flow cytometry crossmatch on outcomes of intestinal/multivisceral transplantation: role anti-IL-2 receptor antibody
10.1097/tp.0b013e3182888df0 · 2013
Targeting B cells for inflammatory bowel disease treatment: back to the future
10.1016/j.coph.2020.10.002 · 2020
Adaptive immunity: B cells and antibodies
2013
B-cell induction therapies in intestinal transplantation
10.1016/j.gtc.2024.01.001 · 2024
Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients
10.1111/tan.12735 · 2016
